Single User

Idiopathic Pulmonary Fibrosis (IPF) 2015-2020

Lung, Respiratory & Breathing Disorders

Epiomic Insights for Idiopathic Pulmonary Fibrosis delivers a top line snapshot of the market potential for this difficult to quantify patient population. With a growing number of therapeutic products in development to address this condition, the ability to quantify the potential in terms of patients, is essential for commercial success.

Sourcing data from our Epiomic Patient segmentation database, we are able to reference relevant clinical trial data and patient registries to provide a picture of the total prevalent population across 8 major global markets. This one-page synopsis developed by our team of analysts delivers a current overview of the disease and risk factors with a perspective on the future drivers of the patient population. Key comorbid conditions of the disease likely to impact use of future therapeutic agents are also included in easy to understand graphics.

This style of report is ideal for companies entering a new market segment or disease area of which they have limited knowledge. Alternatively, companies considering investing in healthcare innovation may benefit from a high-level, accurate overview of the market to determine likely commercial potential of such an investment.